In 2008, the NIH funded the establishment of the Dominantly Inherited Alzheimer Network (DIAN, www.dian-info.org), an international network of leading research centers to investigate dominantly inherited AD. In 2012, the DIAN-TU (Trials Unit) launched the first prevention trials for autosomal dominant AD. The DIAN-TU has developed an adaptive design to test multiple AD targets with the goal of prevention and intervention of cognitive decline in autosomal dominant AD.
The DIAN Expanded Registry (www.DIANXR.org ) is an international participant and researcher registry for DIAN-TU trials. The scientific knowledge gained from secondary prevention trials is likely to inform about the cause of AD, validate biomarkers to accelerate treatment development, and determine the effects of treating AD early.
Randall Bateman, MD
Thursday, May 30, 2013 at 11:00 a.m.
Douglas Hall, Douglas Institute
How to get to the Douglas
May 21, 2013